Antibody kinetics and clinical course of COVID-19 a prospective observational study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 33750984.
- Also identified by DOI 10.1371/journal.pone.0248918 and PMC identifier 7984607.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Serological response and association to clinical manifestation is important for understanding the pathogenesis of COVID-19. A prospective observational study was conducted where antibody responses of IgG and IgA towards SARS-CoV-2 spike protein were studied over time in patients with COVID-19. Possible associations between antibody titers and outcome were analyzed. Forty patients with COVID-19, hospitalized at Skåne University hospital, Sweden, between April and June 2020 were included. IgG antibody responses were detected for all patients with the highest levels four weeks after COVID-19 diagnosis. Levels of IgA were generally higher at diagnosis and decreased towards baseline 4 weeks after confirmed COVID-19. Patients with severe COVID-19 had higher levels of antibodies directed against SARS-CoV-2 spike protein compared with patients with mild disease. IgG and IgA antibodies towards the spike protein follow different kinetics during COVID-19 and patients with severe disease develop higher antibody levels.
Medical subject headings
- Antibodies, Viral
- COVID-19